Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Webinar | The Impact of Patent Term Extension on Litigation Under the Hatch-Waxman Act: A Look at the Federal Circuit’s Recent Decision in Biogen v. Banner Life Scis.

Thursday, August 13th, 2020, 1:30 pm EDT

Webinar | The Impact of Patent Term Extension on Litigation Under the Hatch-Waxman Act: A Look at the Federal Circuit’s Recent Decision in Biogen v. Banner Life Scis.

This webinar is taking place on: Thursday, August 13th, 2020, 1:30 pm EDT

Section 156 of the Patent Act provides for a patent term extension for FDA-regulated products  to compensate for delays in obtaining approval. But what constitutes a “product” under this regulatory scheme? In a recent decision, the Federal Circuit relied on the definition of Section 156, holding that a ‘product’ means the ‘active ingredient… including any salt or ester of the active ingredient’ without expanding the definition and does not include any metabolite of the active ingredient of the product or its de-esterfied form.

On Thursday, August 13, Fish attorneys Robert Oakes and Kelly Allenspach Del Dotto will review the case and its implications for Hatch-Waxman litigation. Among other topics, our speakers will discuss:

  • The purpose behind the patent term extension provision of 35 U.S.C. § 156
  • Section 156’s restrictions on patent term extension and what the statute defines as a “product”
  • The Biogen Int’l GmbH. v. Banner Life Scis. LLC decision, and the impact it could have on Hatch-Waxman litigation

Register today!

Thursday, August 13, 2020

1:30 – 2:30 pm EDT

To register, please click here.

Fish & Richardson will apply for 1.0 hour of CLE credit.

If you have any questions, please contact Jane Lundberg.

Related Services
Related Industries
Related Offices